• In June 2026, Anterix reported fourth-quarter sales of US$1.96 million and full-year sales of US$6.50 million, with net income rising to US$18.52 million for the quarter and US$90.64 million for the year, alongside the completion of a share repurchase program totaling 691,534 shares for US$23.26 million.
• Beyond the headline figures, Anterix’s shift to profitability, new utility contracts for its Private LTE and spectrum solutions, and a cash balance above US$98 million with no debt underline how its spectrum commercialization efforts are increasingly translating into earnings and financial flexibility.
• Next, we’ll examine how Anterix’s move to full-year profitability and new utility contracts could reshape its pre-existing investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Anterix Investment Narrative Recap

Anterix’s story still comes down to whether utilities keep adopting its 900 MHz spectrum and Private LTE solutions fast enough to monetize a largely untapped asset base. The move to full year profitability and higher spectrum revenue is encouraging, but the biggest near term catalyst remains converting new utility wins into cash, while the key risk is that noncash gains and slow contract timing could make recent earnings harder to repeat if deal flow softens.

In that context, the latest earnings release matters because it pairs profitability with concrete progress, including four new utility contracts and a cash balance above US$98 million with no debt. Those contracts directly support the spectrum commercialization and CatalyX adoption story, even as the completed US$23.26 million buyback quietly tightens the share count around whatever future cash flows Anterix can generate.

Yet, against this backdrop of new profits and contracts, investors should be aware that a heavy reliance on noncash spectrum conversion gains means reported earnings could look very different if...

Anterix's narrative projects $6.9 million revenue and $935.0 thousand earnings by 2028. This requires 5.3% yearly revenue growth and a $94.7 million earnings decrease from $95.6 million today.

Uncover how Anterix's forecasts yield a $55.33 fair value, a 33% downside to its current price.

Exploring Other Perspectives

The most pessimistic analysts were previously modeling only about US$6.4 million of revenue and roughly US$0.9 million of earnings by 2029, so if you are worried about how slowly the remaining 85 percent of spectrum gets monetized, this latest profitability surprise may or may not shift that cautious view once the new contracts and cash flows are fully reassessed.

Explore 3 other fair value estimates on Anterix - why the stock might be worth 33% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Anterix research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Anterix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Anterix's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.